Global Wellness’ KaleidoMyco Brand Introduces FIRST EVER Effervescent Tablets Combining Functional Mushrooms + Hemp Extract

Vancouver, British Columbia, April 12, 2022 – Global Wellness Strategies Inc. (CSE: GWS) (Frankfurt:O3X4) (OTCQB: GWSFF) (“Global” or the “Company”) today announces their brand KaleidoMyco will be launching their proprietary fizz tablets this month to the American marketplace. KaleidoMyco is focused on working with doctors and integrative medical practitioners in a collaborative effort in the discovery of products combining mycology formulas with hemp extract derived cannabinoids focused on health and wellness.

“In the competitive global space of plant based medicines being the first mover has plenty of advantages. The strong team of mycologists and scientists took near a year to perfect the fizz tablets launching. We congratulate them on all their efforts and look forward to sharing their successes together and helping them create worldwide sales distribution networks.“ said Meris Kott, CEO Global Wellness Strategies.

Hemp infused medicinal mushroom products aka functional mushrooms are increasingly relevant, because of their ancient healing powers on an array of modern-day ailments. Taking these two powerful plant medicines together enables one to experience enhanced effects. The synergistic combination of both a  hemp-derived blend plus medicinal mushrooms is amazing. An immunity boost, increased cognitive focus, de-stress affect and balanced energy are all benefits of functional mushrooms; while hemp benefits can also include decreased anxiety, reduced pain and improved sleep. KaleidoMyco has developed the first-ever dissolvable hemp infused myco tablets to enter the effervescent category. The tablets dissolve quickly in a glass of water or any beverage hot or cold, adding effervescence and flavor, and are an excellent way to supplement a healthy diet with an array of complementary and synergistic ingredients. The first 3 SKUs are a combo 1+1 of 25mg cannabinoids plus 25mg of functional mushrooms flavored by natural citrus, berry and grape. “According to the report published by Allied Market Research, the global functional mushroom market generated $7.98 billion in 2020, and is estimated to reach $19.33 billion by 2030, witnessing a CAGR of 9.3% from 2021 to 2030.” [1]https://www.alliedmarketresearch.com

About Global Wellness Strategies

Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies. 

For further information visit websites:

 www.globalwellnessstrategies.com

Or Contact Meris Kott CEO 604.484.0355 or email to info@globalwellnessstrategies.com

 Further information about the Company is available on www.SEDAR.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

References

References
1 https://www.alliedmarketresearch.com

Announcement

Breaking
News

February 10, 2022

GWS Signs MDMA Supply Agreement with PharmAla Biotech​

The Shanti Therapeutics Focus on Chronic Pain Market with Psychedelics